
The study analyzed 5709 ventilated patients to assess the long-term impact of neuromuscular blockade agents (NMBAs) on mortality. Non-survivors, constituting 48.3% of the sample, were older, had higher Acute Physiology and Chronic Health Evaluation II scores, and longer ventilator use, often exceeding 48 hours with NMBAs. After adjusting for relevant factors, prolonged NMBA use was independently linked to increased mortality risk (adjusted HR: 1.261), especially in patients with a Charlson Comorbidity Index of 3 or higher. The study suggests a potential association between extended NMBA use and heightened long-term mortality in critically ill, ventilated patients, urging further research for validation.
Like
Save
Share